Pharmaceuticals
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
2021-07-26 18:00
4691
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-26 08:00
7792
GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices
ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to contin...
2021-07-23 21:02
9475
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), aKentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will r...
2021-07-23 16:00
2309
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
2021-07-22 21:50
10606
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high...
2021-07-22 13:00
4309
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-07-22 09:27
3517
Joysbio's COVID-19 RAPID tests detect NEW SARS-COV-2 variants
TIANJIN, China, July 22, 2021 /PRNewswire/ -- Joysbio, one of the world's leading manufacturers of lateral flow rapid test kits, has proven that their SARS-CoV-2 (COVID-19) antigen tests can detect new variants, including the Delta variant that's sweeping the world. With over 100 million tests so...
2021-07-22 08:37
3867
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients w...
2021-07-22 08:30
4079
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...
2021-07-21 22:00
12339
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 307 media titles]
2026-07-15 12:00
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 304 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 291 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 288 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 287 media titles]
2026-07-16 17:49
Most Read
PTCL Group Leadership Meets FinVolution at MWC Shanghai 2026 to Explore Credit Technology for Financial Inclusion in Pakistan
2026-07-14 18:32
11694
NYSE Content Update: Madrona Highlights Private Companies Building AI Apps
2026-07-14 21:26
11389
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
11193
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
2026-07-15 12:00
8419